Cardio-oncology & otherCohort study
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy
- Retrospective cohort study
- propensity-score matched
- single-centre (tertiary care center)
Authors' conclusion
The use of metformin was associated with a lower incidence of HF and overall mortality in patients with DM receiving anthracyclines.
Study context
- Population
- Patients with diabetes mellitus (DM) receiving new anthracycline therapy, tertiary care center, 2008–2021matched
- Participants
- 315 patients
- Exposure
- Metformin vs no metformin
- Outcome
- New-onset symptomatic HF
- Follow-up
- Within 1 year of anthracycline initiation
Main finding
As reported in the abstract
Hazard ratio
0.35
95% CI 0.14–0.90
P = 0.029
Events by group
Metformin vs No metformin
HR 0.35 (95% CI 0.14–0.90); P = 0.029
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Mortality | 0.71 (0.50–1.00) | P = 0.049 | |
| 0.512Hazard ratio (log scale) |
Original publication
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy. JACC CardioOncol. Published 29 August 2023. doi:10.1016/j.jaccao.2023.05.013
Summarised from the published abstract; every number is checked against it